- Home
- ASTL vs PHVS Comparison
ASTL vs PHVS Comparison
Compare ASTL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTL
- PHVS
- Stock Information
- Founded
- ASTL 1902
- PHVS 2015
- Country
- ASTL Canada
- PHVS Netherlands
- Employees
- ASTL N/A
- PHVS N/A
- Industry
- ASTL Steel/Iron Ore
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ASTL Industrials
- PHVS Health Care
- Exchange
- ASTL Nasdaq
- PHVS Nasdaq
- Market Cap
- ASTL 868.8M
- PHVS 862.3M
- IPO Year
- ASTL N/A
- PHVS 2021
- Fundamental
- Price
- ASTL $6.24
- PHVS $16.91
- Analyst Decision
- ASTL
- PHVS Strong Buy
- Analyst Count
- ASTL 0
- PHVS 5
- Target Price
- ASTL N/A
- PHVS $41.60
- AVG Volume (30 Days)
- ASTL 1.5M
- PHVS 50.2K
- Earning Date
- ASTL 03-12-2025
- PHVS 05-07-2025
- Dividend Yield
- ASTL 3.21%
- PHVS N/A
- EPS Growth
- ASTL N/A
- PHVS N/A
- EPS
- ASTL N/A
- PHVS N/A
- Revenue
- ASTL $1,706,096,151.00
- PHVS N/A
- Revenue This Year
- ASTL N/A
- PHVS N/A
- Revenue Next Year
- ASTL $13.28
- PHVS N/A
- P/E Ratio
- ASTL N/A
- PHVS N/A
- Revenue Growth
- ASTL N/A
- PHVS N/A
- 52 Week Low
- ASTL $5.20
- PHVS $14.14
- 52 Week High
- ASTL $12.14
- PHVS $26.57
- Technical
- Relative Strength Index (RSI)
- ASTL 36.91
- PHVS 55.23
- Support Level
- ASTL $5.20
- PHVS $14.49
- Resistance Level
- ASTL $6.93
- PHVS $17.00
- Average True Range (ATR)
- ASTL 0.47
- PHVS 1.32
- MACD
- ASTL -0.07
- PHVS 0.18
- Stochastic Oscillator
- ASTL 42.22
- PHVS 71.95
About ASTL Algoma Steel Group Inc.
Algoma Steel Group Inc is a Canadian company engaged in the production of clean and consistent light gauge steel. The company offers a range of hot and cold rolled steel sheet and plate products. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from domestic sales. The company generates the majority of its revenue from the sale of Steel sheets and strips.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.